Cytokinetics IncCYTK
Buy moreBuy more at today's $56, already under our buy price.
- 4 good· Earnings beat
- 4 to watch· Below 50-day
$55.83−2.70 (−4.61%)
Price at 3:03 PM ET
After hours · opens in 17h 23mNext open: Friday, Nov 13, 9:30 AM ETNASDAQ · Healthcare · Mid-size company
The price we'd buy CYTK at comes with a free account
It also has the whole brief, the scorecard and how the call has moved.A free account gets it on three stocks you pick, plus three long research reports a month.
What would change it
Sources
- From the 10-Q for the quarter to Sep 30, reported Nov 4
- Yahoo Finance daily closes to Nov 9
Any one could move it to Keep
Next report
below15%
sales growth
Compared with the S&P 500
9 points
worse in one day
21 points
worse in five trading days
−10.2% in a yearsince Nov 10, 2025
Latest results
Reported Nov 4 after the close
- EPS
- −$1.37
- vs −$1.50 expected, beat by 8.7%
- The stock
- −13%
- On Nov 5, usually 3.1%
The news behind our call
written Oct 27, 5:22 AM ETOct 27, 5:22 AM ET · 30 articles · 11 sources
Analysts expect Cytokinetics to produce stronger earnings next year.
Most tracked analysts rate Cytokinetics favorably.
Analysts expect future earnings growth.
What changed
From Yahoo Finance, Motley Fool, Financial Times Markets and 2 more
Overview
In plain numbers
- Revenue grew 30% from a year earlier, to $113.3M in the last twelve months.
- It loses $6.25 on every revenue dollar at the operating line, down from a loss of $2.65 in FY 2021.
- It burned $588.6M of free cash in the last twelve months.
- It owes $1.4B and holds $1.1B in cash and investments, so net debt is $296.8M.
Key figures
- Revenue (TTM)
- $113M
- Revenue growth, 1 year
- +29.9%
- Net income
- −$778M
- EPS (diluted)
- −$6.02
- Gross margin
- -259.6%
- Operating margin
- -625.1%
- Return on capital
- -45.8%
- Current ratio
- 3.36
- Buyback yield
- -8.61%
Key facts
- Company value
- $7.5B
- Today's range
- 55.6758.58
- Past year's range
- 53.6987.26
- Yesterday's close
- $58.53
- Swings vs the market
- 0.4×smaller